Wegovy Deal Boosts HIMS, But Margin & Legal Risks Loom

What happened

Hims & Hers stock has surged 41% since its last update, fueled by the Novo Nordisk partnership enabling Wegovy distribution and strong international growth of 969% from acquisitions. However, Q1 revenue growth was a modest 4% to $608M, with U.S. operations declining 8% as the company pivots away from compounded GLP-1s amid regulatory pressure. Gross margin collapsed to 65% from 73% a year ago, driven by a $28.5M inventory write-down and higher fulfillment costs, and management guided for further near-term margin deterioration. The company faces unresolved legal and regulatory overhangs, including an HHS referral to the DOJ and being named in an FDA statement restricting GLP-1 APIs. While early Wegovy traction (125k shipments in six weeks) is promising, the investment thesis hinges on whether branded GLP-1 economics can stabilize margins and overcome enforcement risks.

Implication

Investors should remain cautious despite the stock's recent run. The pivot to branded GLP-1s is a positive step, but gross margin compression and DOJ/FDA investigations create binary downside. Wait for Q2 results to confirm that margins are stabilizing and branded volumes are sustainable before adding exposure. The attractive entry point remains near $18, with a trim level at $32.

Thesis delta

The narrative has shifted from 'compounded GLP-1 growth engine' to 'branded pivot success story,' but the DeepValue analysis shows the market is underestimating the structural margin drag from shipping cadence changes and the unresolved DOJ referral. The stock's 41% gain reflects hope for a smooth transition, yet Q1's net loss and management's cautious guidance suggest the path to profitability is neither quick nor certain. This disconnect between market optimism and fundamental headwinds warrants a WAIT rating until clear evidence of margin stabilization emerges.